Alzamend Neuro Plunges 10.53% Post Reverse Split

On May 14, 2025, Alzamend Neuro's stock experienced a significant drop of 10.53% in pre-market trading.

Alzamend Neuro, Inc. recently performed a 1-for-9 reverse stock split, which means shareholders now hold one share for every nine shares previously held. This move was made to maintain compliance with the minimum bid price requirement of $1.00 per share to continue listing on the Nasdaq Capital Market.

The company has initiated the first of five Phase II clinical studies of AL001, focusing on healthy human subjects. This study is part of a broader effort to explore AL001's potential to deliver lithium more effectively in the brain, with the aim of treating conditions such as Alzheimer's, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. The study is expected to provide topline data by the end of 2025.

In collaboration with Massachusetts General Hospital, Alzamend Neuro is leveraging a novel head coil developed by Tesla Dynamic Coils BV, a key component of the clinical trial. Previous studies in mice have shown that AL001 ensures better brain absorption while maintaining lower levels of lithium in the blood, paving the way for safer and more efficient treatments.